Atria Investments Inc Trims Holdings in Insulet Co. (NASDAQ:PODD)

Atria Investments Inc decreased its position in shares of Insulet Co. (NASDAQ:PODD) by 5.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,533 shares of the medical instruments supplier’s stock after selling 330 shares during the quarter. Atria Investments Inc’s holdings in Insulet were worth $1,288,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Blue Trust Inc. grew its position in shares of Insulet by 84.1% during the 3rd quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock worth $30,000 after buying an additional 58 shares in the last quarter. International Assets Investment Management LLC bought a new position in shares of Insulet during the 2nd quarter worth $32,000. UMB Bank n.a. grew its position in shares of Insulet by 81.0% during the 2nd quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock worth $37,000 after buying an additional 81 shares in the last quarter. CVA Family Office LLC grew its position in shares of Insulet by 138.1% during the 2nd quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier’s stock worth $50,000 after buying an additional 145 shares in the last quarter. Finally, Massmutual Trust Co. FSB ADV grew its position in shares of Insulet by 159.2% during the 2nd quarter. Massmutual Trust Co. FSB ADV now owns 254 shares of the medical instruments supplier’s stock worth $51,000 after buying an additional 156 shares in the last quarter.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. Barclays raised their price objective on Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a research report on Monday, November 11th. UBS Group raised their price objective on Insulet from $211.00 to $223.00 and gave the company a “neutral” rating in a research report on Friday, August 9th. Morgan Stanley raised their price objective on Insulet from $234.00 to $317.00 and gave the company an “overweight” rating in a research report on Monday, November 11th. Piper Sandler raised their price objective on Insulet from $230.00 to $285.00 and gave the company an “overweight” rating in a research report on Tuesday, September 17th. Finally, BTIG Research raised their price objective on Insulet from $260.00 to $270.00 and gave the company a “buy” rating in a research report on Friday, November 8th. Three research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $253.27.

Insulet Trading Down 0.4 %

Shares of NASDAQ:PODD opened at $260.12 on Friday. Insulet Co. has a 52-week low of $160.19 and a 52-week high of $279.40. The stock has a market cap of $18.25 billion, a price-to-earnings ratio of 44.54, a PEG ratio of 4.11 and a beta of 1.22. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. The business has a 50-day moving average price of $237.77 and a 200-day moving average price of $207.72.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.